Filing summary
Period and entity: The supplied filing is Kintara Therapeutics, Inc.’s Form 10-Q for the three months ended September 30, 2020, its fiscal first quarter of 2021—not a Tuhura Biosciences, Inc. filing or 2020 Q1 filing as indicated in the request metadata. Kintara is a clinical-stage cancer drug developer; it reports no revenue to date.
Financial results and position
| Metric | Quarter ended September 30, 2020 | Prior-year quarter |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $1.357 million | $0.721 million |
| General and administrative expense | $1.534 million | $0.914 million |
| Merger costs | $0.500 million | None |
| Acquired in-process R&D expense | $16.094 million | None |
| Net loss | $19.518 million | $1.606 million |
| Loss per share attributable to common stockholders | $1.33 | $0.21 |
| Operating cash used | $4.110 million | $2.266 million |
At September 30, cash and cash equivalents were $22.602 million, working capital was $20.566 million, total assets were $23.131 million, total liabilities were $2.577 million, and stockholders’ equity was $20.554 million. The company had a $500,000 loan bearing 6% interest and maturing June 19, 2021; its reported net carrying amount was $441,000 after deferred financing costs. As a development-stage company without revenue, operating margins are not meaningful.
Cash increased by $20.210 million during the quarter, principally reflecting $21.6 million of net proceeds from a Series C preferred-stock private placement, $994,000 from warrant exercises, and $500,000 in loan proceeds; $969,000 of cash was acquired in the Adgero merger. Operating cash use was higher than in the prior-year quarter.
Material changes and unusual items
- The August 19, 2020 Adgero merger added REM-001 to Kintara’s development portfolio. It was accounted for as an asset acquisition; the acquired $16.094 million of in-process R&D had no alternative future use and was expensed. Merger costs were $500,000 for the quarter.
- R&D expense rose 88% year over year, which management attributed to higher clinical-development, intellectual-property, manufacturing, and stock-based compensation costs, including GCAR study initiation work. G&A expense rose 68%, including higher professional fees, insurance, and stock-based compensation.
- The $25 million gross Series C financing generated approximately $21.6 million net proceeds after costs. Series C preferred shares are convertible into approximately 21.5 million common shares and carry future stock dividends; the placement agent also received warrants. The quarter’s common-stockholder loss includes a $3.181 million noncash deemed dividend from the preferred-stock conversion feature.
- Common shares outstanding were 24,466,000 at quarter-end. In addition, the filing reports substantial outstanding warrants, options, and preferred-stock conversion rights, creating potential dilution.
Outlook, commentary, and risks
- Management said quarter-end cash, together with subsequent warrant-exercise proceeds, was expected to fund planned operations for at least 12 months from issuance of the financial statements; the MD&A separately described cash availability into the fourth quarter of calendar 2021. Future capital needs remain, and management warned that financing may not be available on acceptable terms, potentially requiring delay, reduction, or termination of development programs.
- Planned milestones included a first patient in the VAL-083 GBM AGILE registration study and top-line results from a newly diagnosed GBM Phase 2 study in Q4 2020; recurrent GBM Phase 2 results in Q1 2021; adjuvant GBM results and first REM-001 CMBC lead-in patient in Q2 2021; REM-001 lead-in results in Q4 2021; and possible GBM AGILE Stage 1 graduation in H1 2022. These are forward-looking targets, not reported outcomes.
- Management reported no significant COVID-19 disruption to its ongoing single-site Phase 2 studies to date, while noting limited clinical-monitor access and uncertainty around capital markets. It cautioned that the pandemic’s future operational and financing effects were unknown.
- VAL-083 development risks include clinical efficacy and safety, with myelosuppression—especially thrombocytopenia—identified as a key toxicity. REM-001’s proposed pivotal pathway relies in part on historical studies; management noted FDA questions about the strength of some historical efficacy evidence and plans a new Phase 3 study.
- Disclosure controls and procedures were deemed ineffective at quarter-end because of a material weakness previously described in the company’s fiscal 2020 Form 10-K. The filing reported no material control changes during the quarter. It reported no legal proceedings and no defaults upon senior securities.
Investor verification points
- Confirm the filing identity and reporting period: the source is Kintara’s September 30, 2020 quarter, despite the request metadata naming Tuhura and 2020 Q1.
- Check subsequent filings for actual clinical-trial progress and outcomes against the stated VAL-083 and REM-001 milestones.
- Review cash burn, financing needs, and the stated runway against subsequent spending and capital raises.
- Assess fully diluted share exposure from Series C conversion and dividend rights, warrants, and stock options.
- Review the material weakness disclosure and subsequent remediation status, and track the $500,000 loan’s maturity and repayment.